Estrella Immunopharma (NASDAQ:ESLA) Issues Quarterly Earnings Results

Posted by George Bondi on Aug 14th, 2026

Estrella Immunopharma (NASDAQ:ESLA – Get Free Report) announced its earnings results on Thursday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04, FiscalAI reports.

Estrella Immunopharma Stock Performance

NASDAQ:ESLA opened at $0.72 on Friday. The firm has a market cap of $31.18 million, a P/E ratio of -2.13 and a beta of 0.88. Estrella Immunopharma has a fifty-two week low of $0.68 and a fifty-two week high of $3.15. The firm has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $1.14.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.00.

Read Our Latest Stock Report on Estrella Immunopharma

Hedge Funds Weigh In On Estrella Immunopharma

A number of hedge funds have recently added to or reduced their stakes in the company. Quadrature Capital Ltd purchased a new stake in Estrella Immunopharma during the 4th quarter valued at $43,000. BlackRock Inc. purchased a new position in Estrella Immunopharma in the 2nd quarter worth about $54,000. State Street Corp raised its position in Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after buying an additional 20,900 shares during the last quarter. XTX Topco Ltd lifted its stake in Estrella Immunopharma by 376.9% during the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after acquiring an additional 39,099 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Estrella Immunopharma during the 4th quarter valued at about $88,000. 0.35% of the stock is currently owned by hedge funds and other institutional investors.

About Estrella Immunopharma

(Get Free Report)

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.